Dosing Weight and Pre-Calculated Dose Aids in the European Resuscitation Council Guidelines 2025 Paediatric Life Support: A Document Analysis, Evidence Review and Reference-Chart Modelling Study

Introduction: The European Resuscitation Council (ERC) Guidelines 2025 Paediatric Life Support prefer ideal body weight (IBW) for hydrophilic drugs and no longer explicitly recommend pre-calculated dose aids. Objective: To examine what the guidelines state and cite, the evidence, and resulting dose differences. Methods: An exploratory study combining a document analysis of the ERC paediatric guidelines 2015–2025 and 20 comparator documents; a structured, non-systematic evidence review; and a deterministic calculation, from World Health Organization growth references (2–15 years), of total body weight (TBW) at −2 to +3 standard deviations (SD) of body mass index-for-age relative to IBW. Results: The IBW statement (explanatory text only) has no reference, method or threshold; recommended estimation methods return TBW. At 2–10 years, TBW-based doses exceeded IBW-based doses by 18–36% at +2 SD and 28–71% at +3 SD (up to 40% and 78% at 11–15 years); at −2 SD they were 14–22% lower. These are differences between intended doses, not administration errors. Our searches identified no pharmacokinetic study of adrenaline in children with obesity, no comparison of dosing scalars and no study showing harm from such differences. Explicit pre-calculated dose advice (2021) gave way, unlisted among the changes, to a system-level recommendation of standardised drug calculations and cognitive aids, which the guideline retains. In two before–after evaluations of one dosing ruler, threefold deviations fell from 22.0% to 2.2% and 9.9%; deviations above 20% did not. Conclusions: For children with obesity aged 2–10 years, the guideline points to two dosing weights differing by about 20–70%; within the limits of a non-systematic search, we found no pharmacokinetic or outcome data favouring either. Guideline groups may wish to consider referencing or withdrawing the statement, defining any retained IBW method and naming pre-calculated, volume-based dose aids.

Authors

Institutions

Publication Details

Journal
Children
Published
2026-11-18
DOI
https://doi.org/10.3390/children13111605
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dosing Weight and Pre-Calculated Dose Aids in the European Resuscitation Council Guidelines 2025 Paediatric Life Support: A Document Analysis, Evidence Review and Reference-Chart Modelling Study

Daniel Sosiński, Marzena Wojewódzka‐Żeleźniakowicz, Jerzy Robert Ładny, Adam Jakubowski
Children
Pharmaceutical studies and practices
article

Dosing Weight and Pre-Calculated Dose Aids in the European Resuscitation Council Guidelines 2025 Paediatric Life Support: A Document Analysis, Evidence Review and Reference-Chart Modelling Study

Daniel Sosiński, Marzena Wojewódzka‐Żeleźniakowicz, Jerzy Robert Ładny, Adam Jakubowski
article en

Abstract

Introduction: The European Resuscitation Council (ERC) Guidelines 2025 Paediatric Life Support prefer ideal body weight (IBW) for hydrophilic drugs and no longer explicitly recommend pre-calculated dose aids. Objective: To examine what the guidelines state and cite, the evidence, and resulting dose differences. Methods: An exploratory study combining a document analysis of the ERC paediatric guidelines 2015–2025 and 20 comparator documents; a structured, non-systematic evidence review; and a deterministic calculation, from World Health Organization growth references (2–15 years), of total body weight (TBW) at −2 to +3 standard deviations (SD) of body mass index-for-age relative to IBW. Results: The IBW statement (explanatory text only) has no reference, method or threshold; recommended estimation methods return TBW. At 2–10 years, TBW-based doses exceeded IBW-based doses by 18–36% at +2 SD and 28–71% at +3 SD (up to 40% and 78% at 11–15 years); at −2 SD they were 14–22% lower. These are differences between intended doses, not administration errors. Our searches identified no pharmacokinetic study of adrenaline in children with obesity, no comparison of dosing scalars and no study showing harm from such differences. Explicit pre-calculated dose advice (2021) gave way, unlisted among the changes, to a system-level recommendation of standardised drug calculations and cognitive aids, which the guideline retains. In two before–after evaluations of one dosing ruler, threefold deviations fell from 22.0% to 2.2% and 9.9%; deviations above 20% did not. Conclusions: For children with obesity aged 2–10 years, the guideline points to two dosing weights differing by about 20–70%; within the limits of a non-systematic search, we found no pharmacokinetic or outcome data favouring either. Guideline groups may wish to consider referencing or withdrawing the statement, defining any retained IBW method and naming pre-calculated, volume-based dose aids.

ChildrenVol. 13(11)
Medical University of Białystok (PL), University Clinical Hospital In Bialystok (PL)
Good health and well-being
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon